Review



human bmp6  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    R&D Systems human bmp6
    Human Bmp6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 115 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+bmp+6/Recombinant+Human+BMP-6+Protein/us12612452-522-3-6
    Average 95 stars, based on 115 article reviews
    human bmp6 - by Bioz Stars, 2026-09
    95/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: Optimizations for Identifying Reference Genes in Bone and Cartilage Bioengineering
    Article Snippet: .. The chondrogenic differentiation medium consisted of normal growth medium supplemented with 10 ng/mL recombinant human BMP-6 (R&D Systems, Minneapolis, MN,USA), 10 ng/mL recombinant human TGF-β3 (R&D Systems), 100 nM dexamethasone (Sigma-Aldrich, St. Louis, MI, USA), 50μg/mL L-ascorbic acid-2phosphate (Sigma-Aldrich), 40μg/mL L-proline (Sigma-Aldrich), ITS+1(10 mg/L insulin, 5.5 mg/L transferrin, 4.7μg/mL linoleic acid, 0.5 mg/mL bovine serum albumin, and 5μg/L selenium) (Sigma-Aldrich) [43-46]; the osteogenic differentiation medium consisted of normal growth medium supplemented with 50μg/mL L-ascorbic acid-2-phosphate (Sigma-Aldrich), 1 mM L-glutamine (Sigma-Aldrich), 10 mM β-glycerophosphate (SigmaAldrich) and 100 nM dexamethasone (Sigma-Aldrich) [47]; the normal medium was DMEM supplemented with 3% P/S. ..

    Article Title: BMP6 Promotes the Secretion of 17 Beta-Estradiol and Progesterone in Goat Ovarian Granulosa Cells
    Article Snippet: .. DME/F-12 cell culture medium (HyClone, Logan, UT, USA), Fetal bovine serum (HyClone, Logan, UT, USA), Trypsin (HyClone, Logan, UT, USA), FSHR immunohistochemical kit (anti-rabbit) (Xuanya Bio, Shanghai, China), PCNA Rabbit pAb (Bioworld, St. Louis, MN, USA), β-Actin Rabbit pAb (Proteintech, Wuhan, China), Anti-Rabbit IgG (H+L) (Proteintech, Wuhan, China), BeyoClickTM EdU-594 (Beyotime, Shanghai, China), Recombinant Human BMP-6 (R&D Systems, Minneapolis, MN, USA), Annexin V-FITC/PI, Protein Marker (Solarbio, Beijing, China), RNAiso, Prime ScriptTM RT reagent Kit with gDNA Eraser, and TB GreenTM Premix Ex TaqTM III (TaKaRa, Kusatsu, Japan). ..

    Article Title: Mutual Effects of Orexin and Bone Morphogenetic Proteins on Gonadotropin Expression by Mouse Gonadotrope Cells
    Article Snippet: .. Recombinant human BMP-6 and BMP-15 were purchased from R&D Systems Inc. (Minneapolis, MN, USA). .. Human orexin A was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan) and GnRH human acetate salt was purchased from Sigma-Aldrich Co. Ltd. (St. Louis, MO, USA).

    Article Title: Activin A promotes the development of acquired heterotopic ossification and is an effective target for disease attenuation in mice
    Article Snippet: .. Briefly, growth factor-reduced, phenol red-free Matrigel (Corning) was mixed with: recombinant human bone morphogenetic protein-2 (0.25 μg) (rhBMP2; Gene Script Corp); recombinant human BMP-6 (0.1 μg) (rhBMP6; R&D Systems); recombinant activin A (Act A; 1 μg R&D Systems); rhBMP2 (0.25 μg) plus Act A (0.25 or 1.0 μg; R&D Systems); or rhBMP6 (0.1 μg) plus Act A (0.25 or 1 μg) per 250 μl. .. For experiments utilizing activin A neutralizing monoclonal antibody (nActA.Ab; IgG2b isotype; Biolegend), Matrigel was pre-mixed with: rhBMP2 (0.25 μg) plus mouse pre-immune control IgG2b isotype antibody (25 μg; Biolegend); rhBMP2 (0.25 μg) plus nActA.Ab (25 μg); rhBMP6 (0.1 μg) plus pre-immune control IgG2b isotype (25 μg); or rhBMP6 (0.1 μg) plus nActA.Ab (25 μg).

    Article Title: VHH for application in tissue repair, organ regeneration, organ replacement and tissue engineering
    Article Snippet: .. Upon reaching confluence (4 days elapsed), cells were culture for 3 days stimulated with ascorbic acid (50 μg/ml) and recombinant human BMP-6 (100 ng/ml; R&D Systems) in the presence or absence of VHHs directed against BMPs. .. Cells were also cultured in the presence of BMP-6 and Wnt antagonists (rh-SOST or rh-DKK1; R&D Systems) in the presence or absence of VHHs selected against SOST or DKK1, respectively.

    Article Title: Oxytocin enhances progesterone production with upregulation of BMP-15 activity by granulosa cells.
    Article Snippet: To elucidate the reproductive role of oxytocin (OXT) in ovarian steroidogenesis and its functional interaction with bone morphogenetic proteins (BMPs), the effects of OXT on ovarian steroidogenesis were investigated by utilizing primary culture of rat granulosa cells and human granulosa KGN cells.. Here we revealed that the OXT receptor was expressed in both rat and human granulosa cells and that OXT treatment significantly increased follicle-stimulating hormone (FSH)and forskolin (FSK)-induced progesterone production, but not estradiol production, by rat and human granulosa cells, respectively.. In accordance with the effects of OXT on progesterone production, OXT enhanced mRNA expression of CYP11A1 and HSD3B2 induced by FSK in human granulosa cells.

    Article Title: Mutual Effects of Orexin and Bone Morphogenetic Proteins on Gonadotropin Expression by Mouse Gonadotrope Cells.
    Article Snippet: .. Recombinant human BMP-6 and BMP-15 were purchased from R&D Systems Inc. (Minneapolis, MN, USA). .. Human orexin A was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan) and GnRH human acetate salt was purchased from SigmaAldrich Co. Ltd. (St. Louis, MO, USA).

    Cell Culture:

    Article Title: BMP6 Promotes the Secretion of 17 Beta-Estradiol and Progesterone in Goat Ovarian Granulosa Cells
    Article Snippet: .. DME/F-12 cell culture medium (HyClone, Logan, UT, USA), Fetal bovine serum (HyClone, Logan, UT, USA), Trypsin (HyClone, Logan, UT, USA), FSHR immunohistochemical kit (anti-rabbit) (Xuanya Bio, Shanghai, China), PCNA Rabbit pAb (Bioworld, St. Louis, MN, USA), β-Actin Rabbit pAb (Proteintech, Wuhan, China), Anti-Rabbit IgG (H+L) (Proteintech, Wuhan, China), BeyoClickTM EdU-594 (Beyotime, Shanghai, China), Recombinant Human BMP-6 (R&D Systems, Minneapolis, MN, USA), Annexin V-FITC/PI, Protein Marker (Solarbio, Beijing, China), RNAiso, Prime ScriptTM RT reagent Kit with gDNA Eraser, and TB GreenTM Premix Ex TaqTM III (TaKaRa, Kusatsu, Japan). ..

    Immunohistochemical staining:

    Article Title: BMP6 Promotes the Secretion of 17 Beta-Estradiol and Progesterone in Goat Ovarian Granulosa Cells
    Article Snippet: .. DME/F-12 cell culture medium (HyClone, Logan, UT, USA), Fetal bovine serum (HyClone, Logan, UT, USA), Trypsin (HyClone, Logan, UT, USA), FSHR immunohistochemical kit (anti-rabbit) (Xuanya Bio, Shanghai, China), PCNA Rabbit pAb (Bioworld, St. Louis, MN, USA), β-Actin Rabbit pAb (Proteintech, Wuhan, China), Anti-Rabbit IgG (H+L) (Proteintech, Wuhan, China), BeyoClickTM EdU-594 (Beyotime, Shanghai, China), Recombinant Human BMP-6 (R&D Systems, Minneapolis, MN, USA), Annexin V-FITC/PI, Protein Marker (Solarbio, Beijing, China), RNAiso, Prime ScriptTM RT reagent Kit with gDNA Eraser, and TB GreenTM Premix Ex TaqTM III (TaKaRa, Kusatsu, Japan). ..

    Marker:

    Article Title: BMP6 Promotes the Secretion of 17 Beta-Estradiol and Progesterone in Goat Ovarian Granulosa Cells
    Article Snippet: .. DME/F-12 cell culture medium (HyClone, Logan, UT, USA), Fetal bovine serum (HyClone, Logan, UT, USA), Trypsin (HyClone, Logan, UT, USA), FSHR immunohistochemical kit (anti-rabbit) (Xuanya Bio, Shanghai, China), PCNA Rabbit pAb (Bioworld, St. Louis, MN, USA), β-Actin Rabbit pAb (Proteintech, Wuhan, China), Anti-Rabbit IgG (H+L) (Proteintech, Wuhan, China), BeyoClickTM EdU-594 (Beyotime, Shanghai, China), Recombinant Human BMP-6 (R&D Systems, Minneapolis, MN, USA), Annexin V-FITC/PI, Protein Marker (Solarbio, Beijing, China), RNAiso, Prime ScriptTM RT reagent Kit with gDNA Eraser, and TB GreenTM Premix Ex TaqTM III (TaKaRa, Kusatsu, Japan). ..



    Similar Products

    95
    R&D Systems human bmp6
    Human Bmp6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+bmp+6/Recombinant+Human+BMP-6+Protein/us12612452-522-3-6
    Average 95 stars, based on 1 article reviews
    human bmp6 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    95
    R&D Systems human bmp6 reagents
    Human Bmp6 Reagents, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+bmp+6/Recombinant+Human+BMP-6+Protein/us12612452-457-3-7
    Average 95 stars, based on 1 article reviews
    human bmp6 reagents - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    95
    R&D Systems recombinant human bmp6 protein
    Recombinant Human Bmp6 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+bmp+6/Recombinant+Human+BMP-6+Protein/pm41671472-55-10-14
    Average 95 stars, based on 1 article reviews
    recombinant human bmp6 protein - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    95
    R&D Systems bmp6
    BMP (bone morphogenetic protein) 9 protects from IL (interleukin)-33–induced endothelial-to-mesenchymal transition (EndMT) and induces sST2 (soluble supression of tumorigenicity 2) expression in control pulmonary arterial endothelial cells (PAECs) in vitro. A , Representative immunofluorescent staining of PAEC for CD31 (endothelial marker), SM22α (smooth muscle protein 22-alpha; mesenchymal marker), and 4′,6-diamidino-2-phenylindole (DAPI; nuclei). Cells were treated with BMP9 (1 ng/mL), IL-33 (100 ng/mL), both, or left untreated (control [CTR]) for 3 days. Bar graphs show CD31 and SM22α intensity quantification (n=3). B , sST2 , ST2L , CTGF , and PAI-1 gene expressions in PAECs after 16-hour stimulation with TGF (transforming growth factor)-β (1 ng/mL), activin A (50 ng/mL), or untreated (CTR; technical replicates [t.n.]=3). C , sST2 , ST2L , ID1 , and ID3 gene expressions in PAECs after 3-hour stimulation with BMP4 (50 ng/mL), <t>BMP6</t> (50 ng/mL), BMP9 (1 ng/mL), BMP10 (1 ng/mL), or untreated (CTR; t.n.=3). Statistical analysis: 1-way ANOVA with the Tukey post hoc test; * P <0.05, ** P <0.01, and **** P <0.0001. Data are shown as mean±SD.
    Bmp6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+bmp+6/Recombinant+Human+BMP-6+Protein/pmc12822782-18-4-25
    Average 95 stars, based on 1 article reviews
    bmp6 - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    95
    R&D Systems cf 507 bp 020 cf r d system
    BMP (bone morphogenetic protein) 9 protects from IL (interleukin)-33–induced endothelial-to-mesenchymal transition (EndMT) and induces sST2 (soluble supression of tumorigenicity 2) expression in control pulmonary arterial endothelial cells (PAECs) in vitro. A , Representative immunofluorescent staining of PAEC for CD31 (endothelial marker), SM22α (smooth muscle protein 22-alpha; mesenchymal marker), and 4′,6-diamidino-2-phenylindole (DAPI; nuclei). Cells were treated with BMP9 (1 ng/mL), IL-33 (100 ng/mL), both, or left untreated (control [CTR]) for 3 days. Bar graphs show CD31 and SM22α intensity quantification (n=3). B , sST2 , ST2L , CTGF , and PAI-1 gene expressions in PAECs after 16-hour stimulation with TGF (transforming growth factor)-β (1 ng/mL), activin A (50 ng/mL), or untreated (CTR; technical replicates [t.n.]=3). C , sST2 , ST2L , ID1 , and ID3 gene expressions in PAECs after 3-hour stimulation with BMP4 (50 ng/mL), <t>BMP6</t> (50 ng/mL), BMP9 (1 ng/mL), BMP10 (1 ng/mL), or untreated (CTR; t.n.=3). Statistical analysis: 1-way ANOVA with the Tukey post hoc test; * P <0.05, ** P <0.01, and **** P <0.0001. Data are shown as mean±SD.
    Cf 507 Bp 020 Cf R D System, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+bmp+6/Recombinant+Human+BMP-6+Protein/pmc12219002-123-15-17
    Average 95 stars, based on 1 article reviews
    cf 507 bp 020 cf r d system - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    95
    R&D Systems recombinant human bmp 6 protein
    BMP (bone morphogenetic protein) 9 protects from IL (interleukin)-33–induced endothelial-to-mesenchymal transition (EndMT) and induces sST2 (soluble supression of tumorigenicity 2) expression in control pulmonary arterial endothelial cells (PAECs) in vitro. A , Representative immunofluorescent staining of PAEC for CD31 (endothelial marker), SM22α (smooth muscle protein 22-alpha; mesenchymal marker), and 4′,6-diamidino-2-phenylindole (DAPI; nuclei). Cells were treated with BMP9 (1 ng/mL), IL-33 (100 ng/mL), both, or left untreated (control [CTR]) for 3 days. Bar graphs show CD31 and SM22α intensity quantification (n=3). B , sST2 , ST2L , CTGF , and PAI-1 gene expressions in PAECs after 16-hour stimulation with TGF (transforming growth factor)-β (1 ng/mL), activin A (50 ng/mL), or untreated (CTR; technical replicates [t.n.]=3). C , sST2 , ST2L , ID1 , and ID3 gene expressions in PAECs after 3-hour stimulation with BMP4 (50 ng/mL), <t>BMP6</t> (50 ng/mL), BMP9 (1 ng/mL), BMP10 (1 ng/mL), or untreated (CTR; t.n.=3). Statistical analysis: 1-way ANOVA with the Tukey post hoc test; * P <0.05, ** P <0.01, and **** P <0.0001. Data are shown as mean±SD.
    Recombinant Human Bmp 6 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+bmp+6/Recombinant+Human+BMP-6+Protein/pm40607117-62-44-49
    Average 95 stars, based on 1 article reviews
    recombinant human bmp 6 protein - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    Image Search Results


    BMP (bone morphogenetic protein) 9 protects from IL (interleukin)-33–induced endothelial-to-mesenchymal transition (EndMT) and induces sST2 (soluble supression of tumorigenicity 2) expression in control pulmonary arterial endothelial cells (PAECs) in vitro. A , Representative immunofluorescent staining of PAEC for CD31 (endothelial marker), SM22α (smooth muscle protein 22-alpha; mesenchymal marker), and 4′,6-diamidino-2-phenylindole (DAPI; nuclei). Cells were treated with BMP9 (1 ng/mL), IL-33 (100 ng/mL), both, or left untreated (control [CTR]) for 3 days. Bar graphs show CD31 and SM22α intensity quantification (n=3). B , sST2 , ST2L , CTGF , and PAI-1 gene expressions in PAECs after 16-hour stimulation with TGF (transforming growth factor)-β (1 ng/mL), activin A (50 ng/mL), or untreated (CTR; technical replicates [t.n.]=3). C , sST2 , ST2L , ID1 , and ID3 gene expressions in PAECs after 3-hour stimulation with BMP4 (50 ng/mL), BMP6 (50 ng/mL), BMP9 (1 ng/mL), BMP10 (1 ng/mL), or untreated (CTR; t.n.=3). Statistical analysis: 1-way ANOVA with the Tukey post hoc test; * P <0.05, ** P <0.01, and **** P <0.0001. Data are shown as mean±SD.

    Journal: Hypertension (Dallas, Tex. : 1979)

    Article Title: BMP9 Modulates IL-33 Signaling to Mitigate EndMT in Pulmonary Arterial Hypertension

    doi: 10.1161/HYPERTENSIONAHA.125.24916

    Figure Lengend Snippet: BMP (bone morphogenetic protein) 9 protects from IL (interleukin)-33–induced endothelial-to-mesenchymal transition (EndMT) and induces sST2 (soluble supression of tumorigenicity 2) expression in control pulmonary arterial endothelial cells (PAECs) in vitro. A , Representative immunofluorescent staining of PAEC for CD31 (endothelial marker), SM22α (smooth muscle protein 22-alpha; mesenchymal marker), and 4′,6-diamidino-2-phenylindole (DAPI; nuclei). Cells were treated with BMP9 (1 ng/mL), IL-33 (100 ng/mL), both, or left untreated (control [CTR]) for 3 days. Bar graphs show CD31 and SM22α intensity quantification (n=3). B , sST2 , ST2L , CTGF , and PAI-1 gene expressions in PAECs after 16-hour stimulation with TGF (transforming growth factor)-β (1 ng/mL), activin A (50 ng/mL), or untreated (CTR; technical replicates [t.n.]=3). C , sST2 , ST2L , ID1 , and ID3 gene expressions in PAECs after 3-hour stimulation with BMP4 (50 ng/mL), BMP6 (50 ng/mL), BMP9 (1 ng/mL), BMP10 (1 ng/mL), or untreated (CTR; t.n.=3). Statistical analysis: 1-way ANOVA with the Tukey post hoc test; * P <0.05, ** P <0.01, and **** P <0.0001. Data are shown as mean±SD.

    Article Snippet: Human recombinant BMP4 (314-BP-010/CF), BMP6 (507-BP-020/CF), BMP9 (3209-BP-010/CF), BMP10 (2926-BP-025/CF), activin A (338-AC-010/CF), TGF-b1 (240-B-010/CF), and recombinant human soluble ST2/IL-33R Fc (523-ST-100) were obtained from R&D Systems.

    Techniques: Expressing, Control, In Vitro, Staining, Marker

    BMP (bone morphogenetic protein) 9 protects from IL (interleukin)-33–induced endothelial-to-mesenchymal transition (EndMT) and induces sST2 (soluble supression of tumorigenicity 2) expression in pulmonary arterial endothelial cells (PAECs) from patients with pulmonary arterial hypertension (PAH) in vitro. A , Representative immunofluorescent staining of PAH PAEC for CD31 (endothelial marker), SM22α (smooth muscle protein 22-alpha; mesenchymal marker), and 4′,6-diamidino-2-phenylindole (DAPI). Cells were treated with BMP9 (1 ng/mL), IL-33 (100 ng/mL), both, or left untreated (control [CTR]) for 3 days. Bar graphs show quantification of CD31 and SM22α intensity (technical replicates [t.n.]=3). B , sST2 , ST2L , CTGF , and Pai-1 gene expressions in PAH PAECs s after 16-hour stimulation with TGF (transforming growth factor)-β (1 ng/mL), activin A (50 ng/mL), or untreated (CTR; t.n.=3). C , sST2 , ST2L , ID1 , and ID3 gene expressions in PAH PAECs after 3-hour stimulation with BMP4 (50 ng/mL), BMP6 (50 ng/mL), BMP9 (1 ng/mL), BMP10 (1 ng/mL), or untreated (CTR; t.n.=3). Statistical analysis: 1-way ANOVA with the Tukey post hoc test; P <0.05, * P <0.01, ** P <0.001, and *** P <0.0001. Data are shown as mean±SD.

    Journal: Hypertension (Dallas, Tex. : 1979)

    Article Title: BMP9 Modulates IL-33 Signaling to Mitigate EndMT in Pulmonary Arterial Hypertension

    doi: 10.1161/HYPERTENSIONAHA.125.24916

    Figure Lengend Snippet: BMP (bone morphogenetic protein) 9 protects from IL (interleukin)-33–induced endothelial-to-mesenchymal transition (EndMT) and induces sST2 (soluble supression of tumorigenicity 2) expression in pulmonary arterial endothelial cells (PAECs) from patients with pulmonary arterial hypertension (PAH) in vitro. A , Representative immunofluorescent staining of PAH PAEC for CD31 (endothelial marker), SM22α (smooth muscle protein 22-alpha; mesenchymal marker), and 4′,6-diamidino-2-phenylindole (DAPI). Cells were treated with BMP9 (1 ng/mL), IL-33 (100 ng/mL), both, or left untreated (control [CTR]) for 3 days. Bar graphs show quantification of CD31 and SM22α intensity (technical replicates [t.n.]=3). B , sST2 , ST2L , CTGF , and Pai-1 gene expressions in PAH PAECs s after 16-hour stimulation with TGF (transforming growth factor)-β (1 ng/mL), activin A (50 ng/mL), or untreated (CTR; t.n.=3). C , sST2 , ST2L , ID1 , and ID3 gene expressions in PAH PAECs after 3-hour stimulation with BMP4 (50 ng/mL), BMP6 (50 ng/mL), BMP9 (1 ng/mL), BMP10 (1 ng/mL), or untreated (CTR; t.n.=3). Statistical analysis: 1-way ANOVA with the Tukey post hoc test; P <0.05, * P <0.01, ** P <0.001, and *** P <0.0001. Data are shown as mean±SD.

    Article Snippet: Human recombinant BMP4 (314-BP-010/CF), BMP6 (507-BP-020/CF), BMP9 (3209-BP-010/CF), BMP10 (2926-BP-025/CF), activin A (338-AC-010/CF), TGF-b1 (240-B-010/CF), and recombinant human soluble ST2/IL-33R Fc (523-ST-100) were obtained from R&D Systems.

    Techniques: Expressing, In Vitro, Staining, Marker, Control